170 related articles for article (PubMed ID: 29461834)
21. Tirapazamine-embedded polyplatinum(iv) complex: a prodrug combo for hypoxia-activated synergistic chemotherapy.
Guo D; Xu S; Yasen W; Zhang C; Shen J; Huang Y; Chen D; Zhu X
Biomater Sci; 2020 Jan; 8(2):694-701. PubMed ID: 31777870
[TBL] [Abstract][Full Text] [Related]
22. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
24. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
Wang J; Biedermann KA; Wolf CR; Brown JM
Br J Cancer; 1993 Feb; 67(2):321-5. PubMed ID: 8431360
[TBL] [Abstract][Full Text] [Related]
25. Putative electron-affinic radiosensitizers and markers of hypoxic tissue: Synthesis and preliminary in vitro biological characterization of C3-amino-substituted benzotriazine dioxides (BTDOs).
Elsaidi HR; Yang XH; Ahmadi F; Weinfeld M; Wiebe LI; Kumar P
Eur J Med Chem; 2019 Mar; 165():216-224. PubMed ID: 30684798
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
27. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
28. Targeting triple-negative breast cancer with an aptamer-functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies.
Chou YT; Lin CY; Wen JW; Hung LC; Chang YF; Yang CM; Wu LC; Ho JA
J Nanobiotechnology; 2021 Mar; 19(1):89. PubMed ID: 33781277
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
30. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
Walton MI; Workman P
Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
[TBL] [Abstract][Full Text] [Related]
31. Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.
Hay MP; Shin HN; Wong WW; Sahimi WW; Vaz ATD; Yadav P; Anderson RF; Hicks KO; Wilson WR
Molecules; 2019 Jul; 24(14):. PubMed ID: 31295864
[TBL] [Abstract][Full Text] [Related]
32. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
[TBL] [Abstract][Full Text] [Related]
33. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Walton MI; Sugget N; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
[TBL] [Abstract][Full Text] [Related]
34. Enzymology of tirapazamine metabolism: a review.
Patterson AV; Saunders MP; Chinje EC; Patterson LH; Stratford IJ
Anticancer Drug Des; 1998 Sep; 13(6):541-73. PubMed ID: 9755718
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
Cowen RL; Williams KJ; Chinje EC; Jaffar M; Sheppard FC; Telfer BA; Wind NS; Stratford IJ
Cancer Res; 2004 Feb; 64(4):1396-402. PubMed ID: 14973055
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
Lee AE; Wilson WR
Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
39. Spin Trapping Hydroxyl and Aryl Radicals of One-Electron Reduced Anticancer Benzotriazine 1,4-Dioxides.
Qi W; Yadav P; Hong CR; Stevenson RJ; Hay MP; Anderson RF
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164077
[TBL] [Abstract][Full Text] [Related]
40. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines.
Cahill A; White IN
Carcinogenesis; 1990 Aug; 11(8):1407-11. PubMed ID: 2117504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
